|
|
|
|
|||||
|
|
|
Novartis AG (NYSE:NVS) is included among the 12 Best European Dividend Stocks to Buy Now.
On October 31, Morgan Stanley upgraded Novartis AG (NYSE:NVS) to Overweight from Equal Weight, raising its price target to CHF 110 from CHF 108, as reported by The Fly. The firm cited an attractive valuation following the recent market sell-off. The analyst noted that Novartis is improving its portfolio mix ahead of the upcoming Rhapsido launch. While Morgan Stanley expects modest growth in 2026, it anticipates acceleration starting in 2027.
In the third quarter of 2025, Novartis AG (NYSE:NVS) reported revenue of $13.9 billion, up 8% from the same period last year. Free cash flow for Q3 reached $6.2 billion, a 4% increase, supported by stronger net cash from operating activities. Operating income rose 24% to $4.5 billion, driven by higher sales and lower impairments, partially offset by increased R&D spending. Net income increased 23% to $3.9 billion, primarily due to higher operating income.
Looking ahead, Novartis AG (NYSE:NVS) reaffirmed its 2025 guidance, expecting high single-digit sales growth and low-teen growth in core operating income. The company is addressing pipeline challenges as three major drugs, including its blockbuster heart medication Entresto, face generic competition this year. To counter these pressures, Novartis is expanding into cancer and autoimmune therapies and accelerating acquisitions.
Novartis AG (NYSE:NVS) is an innovative medicines company that discovers, develops, and manufactures treatments designed to improve and extend lives while tackling serious diseases.
While we acknowledge the potential of NVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Best 52-Week Low Dividend Stocks to Invest In and 15 Stocks with Highest Dividend to Invest In
Disclosure: None.
| Nov-19 | |
| Nov-17 | |
| Nov-14 | |
| Nov-13 | |
| Nov-12 | |
| Nov-11 | |
| Nov-08 | |
| Nov-06 | |
| Oct-31 | |
| Oct-30 | |
| Oct-29 | |
| Oct-29 | |
| Oct-29 | |
| Oct-28 |
Novartis Slips As Generics Bite Into Its Heart-Failure Drug Sales In Mixed Third Quarter
NVS
Investor's Business Daily
|
| Oct-28 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite